Agilent buys Zymed but could still quit medical sector
This article was originally published in Clinica
Executive Summary
Agilent Technologies, whose share price has fallen by 35% in the past two weeks despite strong sales in all but the medical sector, has "affirmed its commitment to diagnostic cardiology", by agreeing to buy Zymed, a cardiac analysis software technology company. Despite that, Agilent's management confirmed that the company was prepared to leave the healthcare sector if the capital could be redeployed elsewhere.